Following World Lung Cancer Day, RevealDx, a leader in AI characterisation of lung nodules, has announced a distribution agreement and strategic investment of $3.4 million by 4DMedical, expanding access to its flagship product, RevealAI-Lung.
RevealAI-Lung has received MDR Certification, TGA Approval, and FDA clearance. In the transaction with 4DMedical, Chestnut Partners, Inc. served as the exclusive financial advisor to RevealDx.
This news follows 4DMedical’s recent acquisition of Austrian-based contextflow. 4DMedical, a global medical technology company, is revolutionising respiratory care through advanced imaging and artificial intelligence. Contextflow offers advanced chest CT technologies that automate the identification of lung nodules. RevealAI-Lung has been integrated into the contextflow platform and is already operational at several clinical sites across Europe.
The RevealDx technology characterises incidental lung nodules by producing a Malignancy Similarity Index (mSI), a score that helps radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on over 1,500 patients from a variety of cohorts.
“We are excited to announce our new partnership with 4DMedical,” said Chris Wood, CEO of RevealDx. “As we recognise World Lung Cancer Day, this milestone underscores our commitment to helping clinicians identify potentially malignant lung nodules earlier and with greater confidence. The incredible team at 4DMedical and the resources they bring will expand our reach and benefit patients.”
Andreas Fouras, Founder and CEO of 4DMedical said: “For 4DMedical, this is about more than adding products. It is about building a connected ecosystem for cardiopulmonary care. CT:VQ gives physicians physiological insight into how the lung is actually functioning. By surrounding that capability with disease detection, and AI-powered risk stratification, we can help health systems identify the right patients earlier and ensure they receive appropriate care. The result is a platform that has the potential to improve outcomes for patients while increasing utilisation of advanced functional imaging across vital disease areas.”
